Fig. 2: M2-like TAM-targeting capacity of Man-MPs.

a, b Relative PKH67 mean fluorescence intensity (MFI) in RAW264.7 cells (M0 macrophages, a) or BMDMs (M0 BMDMs, b), LPS- and IFN-γ-conditioned RAW264.7 cells (M1-like macrophages, a) or BMDMs (M1-like BMDMs, b), IL-4-conditioned RAW264.7 cells (M2-like macrophages, a) or BMDMs (M2-like BMDMs, b), dendritic DC2.4 cells (a) or bone marrow-derived dendritic cells (BMDCs, b) and H22 cells after treatment with PKH67-labeled MPs or Man-MPs at the concentration of 10 µg protein mL⁻¹ for 4 h. Data are presented as means ± s.d. (n = 3 biologically independent samples; one-way ANOVA followed by Tukey’s HSD post-hoc test). c Relative PKH67 MFI in IL-4-conditioned RAW264.7 cells after treatment with PKH67-labeled MPs or Man-MPs at the concentration of 10 µg protein mL⁻¹ in the presence or absence of 100 μg mL⁻¹ Man for 4 h. Data are presented as means ± s.d. (n = 3 biologically independent samples; one-way ANOVA followed by Tukey’s HSD post-hoc test). d, e, Ex vivo imaging (d) and fluorescence intensity (e) of Cy5 in the organs and tumors of H22 tumor-bearing mice at 24 h after intravenous injection of Cy5-labeled MPs or Man-MPs at the dosage of 15 mg protein kg⁻¹. Scale bars: 1 cm for (d). Data are presented as means ± s.d. for (e). (n = 4 mice per group; unpaired two-tailed Student’s t-test). f Relative PKH26 MFI in M1-like TAMs (CD11b⁺F4/80⁺CD11c⁺ cells), M2-like TAMs (CD11b⁺F4/80⁺CD206⁺ cells), GFP⁺ tumor cells, DCs (CD45⁺F4/80⁻CD11c⁺ cells), CD4⁺ T cells (CD45⁺CD3⁺CD4⁺ cells), CD8⁺ T cells (CD45⁺CD3⁺CD8a⁺ cells), MDSCs (CD45⁺CD11b⁺Gr1⁺ cells) and Tregs (CD45⁺CD4⁺CD25⁺FoxP3⁺ cells) in tumor tissues of GFP-expressing H22 tumor-bearing mice at 24 h after intravenous injeciton of PKH26-labeled MPs or Man-MPs at the dosage of 15 mg protein kg⁻¹. Data are presented as means ± s.d. (n = 4 mice per group; two-way ANOVA followed by Bonferroni’s multiple comparisons post-test). g Relative PKH26 MFI in TAMs, liver Kupffer cells, splenic macrophages, pulmonary macrophages (all these macrophages including TAMs were gated as CD11b⁺F4/80⁺ cells) and splenic DCs (CD45⁺F4/80⁻CD11c⁺ cells) of H22 tumor-bearing mice at 24 h after treatment indicated in (f). Data are presented as means ± s.d. (n = 4 mice per group; two-way ANOVA followed by Bonferroni’s multiple comparisons post-test). Source data are provided as a Source Data file.